Ravichandran, Supriya
Tang, Juanjie
Grubbs, Gabrielle http://orcid.org/0000-0003-4302-9535
Lee, Youri
Pourhashemi, Sara
Hussaini, Laila
Lapp, Stacey A.
Jerris, Robert C.
Singh, Vidisha
Chahroudi, Ann http://orcid.org/0000-0001-7479-9546
Anderson, Evan J. http://orcid.org/0000-0002-1576-4420
Rostad, Christina A.
Khurana, Surender http://orcid.org/0000-0002-0593-7965
Funding for this research was provided by:
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (FDA’s Medical Countermeasures Initiative (MCMi) grant #OCET 2021-1565, FDA’s Perinatal Health Center of Excellence (PHCE) project grant #GCBER005, CBER COVID intramural funds)
Fast Grant from Emergent Ventures at the Mercatus Center of George Mason University
Emory University (Pilot funds)
Article History
Received: 24 March 2021
Accepted: 14 September 2021
First Online: 5 October 2021
Competing interests
: E.J.A. declares receipt of federal funding from the NIAID to his institution to conduct phase I and III SARS-CoV-2 vaccine clinical trials in adults, and has received personal fees from AbbVie, Pfizer and Sanofi Pasteur for consulting. E.J.A. also serves on a safety monitoring board for Kentucky BioProcessing. C.A.R. has received federal funding from the NIAID to her institution to conduct phase I and III SARS-CoV-2 vaccine clinical trials in adults and is a co-inventor on patented RSV vaccine technology, which has been licensed to Meissa Vaccines. The other authors declare no competing interests.
Free to read: This content has been made available to all.